Disease · HP_0003270
Abdominal distention
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Abdominal distention. Diseases, record HP_0003270. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0003270
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Abdominal bloating, Abdominal distension, Abdominal swelling, Belly bloating, Bloating, Distended abdomen
- Open Targets
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ACOTIAMIDE HYDROCHLORIDE | CHEMBL2107308 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| ANISE OIL | CHEMBL2108976 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| LINACLOTIDE | CHEMBL3301675 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PEPPERMINT OIL | CHEMBL2108758 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| RIFAXIMIN | CHEMBL1617 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| MISOPROSTOL | CHEMBL606 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets3
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ACHE | Acetylcholinesterase | 1 | Acetylcholinesterase inhibitor | Approval | https://conductscience.org/library/genes/43 | Drugs and targets |
| GUCY2C | Guanylyl cyclase C | 1 | Heat-stable enterotoxin receptor agonist | Phase 3 | https://conductscience.org/library/genes/2984 | Drugs and targets |
| PTGER3 | Prostaglandin E2 receptor EP3 subtype | 1 | Prostanoid EP3 receptor agonist | Early phase 1 | https://conductscience.org/library/genes/5733 | Drugs and targets |
Trials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01642914 | Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating | Phase 3 | 487 | 2016-04-26 | Chronic Constipation, Constipation | LINACLOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02364830 | Clinical Effectiveness of Enteric Coated(E.C.) Anise-oil on Irritable Bowel Syndrome | Phase 3 | 120 | Irritable Bowel Syndrome | ANISE OIL, PEPPERMINT OIL | Its record names the disease | ClinicalTrials.gov | |
| NCT06772064 | Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating. | Not applicable | 115 | SIBO | RIFAXIMIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04768010 | Misoprostol for Bloating and Distension | Early phase 1 | 0 | Distension, Gas Bloat Syndrome, Constipation | MISOPROSTOL | Its record names the disease | ClinicalTrials.gov | |
| NCT05408910 | Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis | Phase 2/3 | 0 | Cystic Fibrosis, Abdominal Pain, Small Bowel Disease | RIFAXIMIN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0003270
GET https://conductscience.org/api/diseases/v1/HP_0003270/drugs